Coronavirus vaccine - Altimmune
Alternative Names: AdCOVID; Intranasal COVID-19 vaccine - AltimmuneLatest Information Update: 25 Apr 2024
At a glance
- Originator Altimmune
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 21 Dec 2022 Altimmune completes a phase I trial for COVID-2019 infections (Prevention) in USA (Intranasal) (NCT04679909)
- 29 Jun 2021 Immunogenicity and adverse event data from a phase I trial in COVID-2019 infections released by Altimmune
- 26 May 2021 Immunogenicity data from a preclinical trial in COVID-2019 infections released by Altimmune